2007
DOI: 10.4049/jimmunol.179.12.8562
|View full text |Cite
|
Sign up to set email alerts
|

Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis

Abstract: Myasthenia gravis (MG) is a neuromuscular transmission disorder in which damage to acetylcholine receptors (AChR) on motor endplates by autoantibody-induced complement attack causes muscle weakness. To determine whether and, if so, to what extent, blockade of complement cascade at the C5 step ameliorates disease, we evaluated the effect of administering a functionally blocking anti-C5 mAb in passive experimental MG in Lewis rats induced with AChR Ab McAb-3. In contrast to uniform severe weakness at 24 h requir… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
68
0
1

Year Published

2008
2008
2024
2024

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 79 publications
(70 citation statements)
references
References 32 publications
1
68
0
1
Order By: Relevance
“…Complement inhibition therapy with a blocking anti-C5 antibody has shown promise in a rodent model of EAMG. 46 A candidate therapy in our patients would be eculizumab, a monoclonal antibody to C5 that has shown efficacy in paroxysmal nocturnal hemoglobinuria. 47 Potentially, susceptible MG patients would be screened for the polymorphism and as soon as treatment-resistant ophthalmoparesis ensues, appropriate additional anticomplement therapy may be initiated.…”
Section: Discussionmentioning
confidence: 99%
“…Complement inhibition therapy with a blocking anti-C5 antibody has shown promise in a rodent model of EAMG. 46 A candidate therapy in our patients would be eculizumab, a monoclonal antibody to C5 that has shown efficacy in paroxysmal nocturnal hemoglobinuria. 47 Potentially, susceptible MG patients would be screened for the polymorphism and as soon as treatment-resistant ophthalmoparesis ensues, appropriate additional anticomplement therapy may be initiated.…”
Section: Discussionmentioning
confidence: 99%
“…Administration of an antimouse C5 monoclonal antibody protected CD59-deficient mice from passive EAMG in the absence of CD59, the complement regulator that protects self-cells against endogenous C5b-mediated injury [50]. Anti-C5 antibody also is protective in passive EAMG of rats [68].…”
Section: Therapeutic Approaches To Mg By Regulation Of Complementmentioning
confidence: 99%
“…As alluded to previously, EAMG has been inhibited by administration of complement inhibitors [50][51][52]68]. Administration of anti-C1q [64], anti-C6 [51] or sCR1 have been shown to protect rats against EAMG.…”
Section: Therapeutic Approaches To Mg By Regulation Of Complementmentioning
confidence: 99%
See 2 more Smart Citations